Zoledronic Acid for the Treatment of Children With Refractory Central Giant Cell Granuloma

Chien, May; Mascarenhas, Leo; Hammoudeh, Jeffrey A.; Venkatramani, Rajkumar

doi:10.1097/mph.0000000000000380

Cited by 20 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, GCLJ are treated by conservative surgery. Besides surgery, GCLJ are occasionally treated with corticosteroids [85], calcitonin [86,87], bisphosphonates [88], or interferon alpha [89] in addition to denosumab (a RANKL inhibitor) [90], with variable responses [86,91]. Notably, RANKL is expressed in the GCLJ mononuclear cells [92] and its expression by GCLJ mononuclear 'stromal' cells influences the differentiation of monocyte/macrophage precursors into osteoclast-like giant cells [75].…”

Section: Therapeutic Implicationsmentioning

confidence: 99%

Making sense of giant cell lesions of the jaws (GCLJ): lessons learned from next‐generation sequencing

Gomes

Diniz

Bastos

et al. 2019

The Journal of Pathology

View full text Add to dashboard Cite

Next-generation sequencing has revealed mutations in several bone-related lesions and was recently used to uncover the genetic basis of giant cell lesions of the jaws (GCLJ). Consistent with their benign nature, GCLJ show a low tumor mutation burden. They also harbor somatic, heterozygous, mutually exclusive mutations in TRPV4, KRAS, or FGFR1. These signature mutations occur only in a subset of lesional cells, suggesting the existence of a 'landscaping effect', with mutant cells inducing abnormal accumulation of non-mutant cells that form the tumor mass. Osteoclast-rich lesions with histological similarities to GCLJ can occur in the jaws sporadically or in association with genetically inherited syndromes. Based on recent results, the pathogenesis of a subgroup of sporadic GCLJ seems closely related to non-ossifying fibroma of long bones, with both lesions sharing MAPK pathway-activating mutations. In this review, we extrapolate from these recent findings to contextualize GCLJ genetics and we highlight the therapeutic implications of this new information.

show abstract

Section: Therapeutic Implicationsmentioning

confidence: 99%

Making sense of giant cell lesions of the jaws (GCLJ): lessons learned from next‐generation sequencing

Gomes

Diniz

Bastos

et al. 2019

The Journal of Pathology

View full text Add to dashboard Cite

show abstract

“…Its aetiology is still uncertain making it difficult to treat. Several therapies have been proposed in the literature, from corticosteroids, calcitonin, interferons and bisphosphonates (7), to more radical procedures such as surgical enucleation with curettage, and resection (8). It is usually classified as a circumscribed, non-cortical, multilocular and radiolucent lesion.…”

Section: Introductionmentioning

confidence: 99%

Central giant cell granuloma mimicking a periapical lesion of endodontic origin: A case report

et al. 2020

View full text Add to dashboard Cite

This paper aims to report a case in which central giant cell granuloma (CGCG) mimicked a periapical lesion of endodontic origin. An 18‐year‐old female patient was referred for diagnosis and treatment of extensive radiolucent periapical lesion involving 31, 32, 33, 34 and 35 teeth. Clinically, the patient presented slight facial asymmetry and healthy teeth on the affected side with positive response to thermal vitality tests. Thus, an incisional biopsy was performed, which presented a histopathological picture characteristic of a CGCG. The endodontic treatment of the involved teeth was followed by surgical curettage of the lesion. After two years of follow‐up, the patient was asymptomatic, with marked improvement in mandibular symmetry and adequate healing of the lesion. Therefore, the diagnosis of radiolucent periapical lesions must include lesions of endodontic and non‐endodontic origin for better treatment planning and execution.

show abstract

“…Pharmacological agents, including calcitonin [9, 10], IFN-α [8], and denosumab [11], are promising alternatives to surgical management. Pharmacological agents have the potential to decrease the recurrence rate, minimizing the morbidity associated with surgery, and even prevent the need for surgical intervention [9, 12, 13]. A double-blind clinical study reported that calcitonin significantly reduced the recurrence rate of central giant cell granuloma after curettage.…”

Section: Discussionmentioning

confidence: 99%

Radiotherapy for recurrent central Giant cell granuloma: a case report

Zhang

Wang

et al. 2019

Radiat Oncol

View full text Add to dashboard Cite

Background Central giant cell granuloma (CGCG) is a rare, non-neoplastic, benign lesion that exhibits expansive and osteolytic biological behavior. CGCG treatment and management is challenging for clinicians. Case presentation This report presents the treatment and management of recurrent, aggressive CGCG after surgical resection. After informed consent was obtained, the patient underwent radiotherapy. The lesion size was reduced significantly, with no evidence of recurrence or malignant transformation. Conclusions This treatment experience indicates that radiotherapy can be used as a rescue treatment for complicated CGCG involving vital neurovascular structures of the cranial base.

show abstract

Zoledronic Acid for the Treatment of Children With Refractory Central Giant Cell Granuloma

Cited by 20 publications

References 21 publications

Making sense of giant cell lesions of the jaws (GCLJ): lessons learned from next‐generation sequencing

Making sense of giant cell lesions of the jaws (GCLJ): lessons learned from next‐generation sequencing

Central giant cell granuloma mimicking a periapical lesion of endodontic origin: A case report

Radiotherapy for recurrent central Giant cell granuloma: a case report

Contact Info

Product

Resources

About